Show simple item record

dc.contributor.authorHowell, Anthony
dc.date.accessioned2010-09-10T16:01:13Z
dc.date.available2010-09-10T16:01:13Z
dc.date.issued1989
dc.identifier.citationThe relationship between age and the effect of adjuvant therapies in women with primary breast cancer. 1989, 32 Suppl 1:231-7 Horm Resen
dc.identifier.issn0301-0163
dc.identifier.pmid2613208
dc.identifier.doi10.1159/000181354
dc.identifier.urihttp://hdl.handle.net/10541/111035
dc.description.abstractApparent differences in the effectiveness of adjuvant therapies according to age, has led to controversy concerning the optimum treatment for women with breast cancer above and below 50 years of age. The data upon which this controversy is based and the possible reasons why chemotherapy appears more active in young women, whilst endocrine therapy appears more active in older women, is examined.
dc.language.isoenen
dc.subjectAnticancerous Agentsen
dc.subjectBreast Canceren
dc.subject.meshAdult
dc.subject.meshAge Factors
dc.subject.meshAntineoplastic Agents
dc.subject.meshBreast Neoplasms
dc.subject.meshDrug Evaluation
dc.subject.meshFemale
dc.subject.meshHumans
dc.subject.meshMiddle Aged
dc.subject.meshTamoxifen
dc.titleThe relationship between age and the effect of adjuvant therapies in women with primary breast cancer.en
dc.typeArticleen
dc.identifier.eissn1423-0046
dc.contributor.departmentDepartment of Medical Oncology, Christie Hospital, Manchester, UK.en
dc.identifier.journalHormone Researchen
html.description.abstractApparent differences in the effectiveness of adjuvant therapies according to age, has led to controversy concerning the optimum treatment for women with breast cancer above and below 50 years of age. The data upon which this controversy is based and the possible reasons why chemotherapy appears more active in young women, whilst endocrine therapy appears more active in older women, is examined.


This item appears in the following Collection(s)

Show simple item record